Application Nr Approved Date Route Status External Links
NDA021903 None Intravenous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Neoprofen Is Indicated To Close A Clinically Significant Patent Ductus Arteriosus (Pda) In Premature Infants Weighing Between 500 And 1500 G, Who Are No More Than 32 Weeks Gestational Age When Usual Medical Management (E.g., Fluid Restriction, Diuretics, Respiratory Support, Etc.) Is Ineffective. The Clinical Trial Was Conducted Among Infants With An Asymptomatic Pda. However, The Consequences Beyond 8 Weeks After Treatment Have Not Been Evaluated; Therefore, Treatment Should Be Reserved For Infants With Clear Evidence Of A Clinically Significant Pda. Neoprofen Is A Nonsteroidal Anti-Inflammatory Drug Indicated To Close A Clinically Significant Patent Ductus Arteriosus (Pda) In Premature Infants Weighing Between 500 And 1500 G, Who Are No More Than 32 Weeks Gestational Age When Usual Medical Management Is Ineffective. The Clinical Trial Was Conducted Among Infants With An Asymptomatic Pda. However, The Consequences Beyond 8 Weeks After Treatment Have Not Been Evaluated; Therefore, Treatment Should Be Reserved For Infants With Clear Evidence Of A Clinically Significant Pda. (1)

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Ibuprofen Lysine IBUPROFEN LYSINE ZINC2647

Comments